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ABSTRACT Combinatorial chemotherapy is necessary for the treatment of malaria.
However, ﬁnding a suitable partner drug for a new candidate is challenging. Here
we develop an algorithm that identiﬁes all of the gene pairs of Plasmodium falcipa-
rum that possess orthologues in yeast that have a synthetic lethal interaction but
are absent in humans. This suggests new options for drug combinations, particularly
for inhibitors of targets such as P. falciparum calcineurin, cation ATPase 4, or phos-
phatidylinositol 4-kinase.
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There is a persistent need for new antimalarials due to the evolution of drug-resistant parasites. Under the auspices of the Medicines for Malaria Venture
(MMV), new drug candidates that are active against artemisinin-resistant isolates
of Plasmodium falciparum are being developed; the frontrunners are artefenomel,
KAF156, cipargamin, DSM265, MMV390048, ferroquine, and tafenoquine (1, 2).
However, the choice of the right partner drug will be critical for the success of these
new molecules, as the WHO enforces the application of antimalarials in combina-
tion therapy (3). In addition to protecting each other from drug resistance, two
molecules to be combined need to be compatible for coformulation, should have
matching pharmacokinetic proﬁles, and must not have unfavorable polypharma-
cology (4–6). Ideally, the two molecules would potentiate each other, thereby
decreasing the duration of treatment and the required doses. Thus, combinatorial
chemotherapy not only can reduce the risk of drug resistance but also can enhance
drug safety and drug efﬁcacy, enabling the ambitious goal of a “single-exposure
radical cure” (7, 8).
Here we propose to support the matchmaking of antimalarial candidates by learn-
ing from yeast reverse genetics. Saccharomyces cerevisiae is probably the best studied
of all eukaryotes. Only about 20% of its protein-coding genes are essential for growth
on rich medium (9). High-throughput crossing experiments have shown that many
viable S. cerevisiae gene deletion mutants possess synthetic phenotypes, i.e., growth
defects that become apparent only in the absence of another nonessential gene. The
concept of genetic synthetic lethality can be adopted to combination chemotherapy
(8, 10–12). The principal idea is to extrapolate from synthetic lethal gene pairs in S.
cerevisiae to orthologous pairs of genes in P. falciparum, assuming that the combined
inhibition of the respective gene products will produce a synergistic effect. However,
this seemingly straightforward approach is complicated by the fact that S. cerevisiae is
more closely related to Homo sapiens than to P. falciparum (13). Thus, a drug combi-
nation inferred from yeast synthetic genetic lethality might enhance the toxicity to
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humans rather than enhancing the antimalarial efﬁcacy. To avoid such a scenario, we
developed an algorithm to exclude gene pairs that are conserved in H. sapiens.
Yeast synthetic lethal gene pairs were obtained from BioGRID 3.4 (14) and pairs and
groups of orthologous genes from the OrthoMCL 5 database, based on the similarity of
the derived protein sequences (15, 16). Mining the OrthoMCL database with the 16,217
synthetic lethal gene pairs of S. cerevisiae identiﬁed in BioGRID, we found that only
1,505 pairs (9.3%) had direct orthologues in P. falciparum for both gene products (Fig.
1). From this set, we tested all of the proteins for the presence of an orthologue in the
human proteome, again referring to the downloaded OrthoMCL database. This assess-
ment included direct pairwise orthology between the P. falciparum or S. cerevisiae
protein and a H. sapiens protein or indirect orthology in which either the malaria
protein or its yeast orthologue belonged to an OrthoMCL group that also contained a
human protein (Fig. 1). All of the P. falciparum gene pairs for which both gene products
tested positive for direct or indirect human orthology were eliminated. This process
yielded 37 pairs composed of 55 unique P. falciparum proteins that fulﬁlled the
conditions that (i) their direct orthologues in S. cerevisiae exhibit synthetic lethality and
(ii) at least one of the two proteins has neither a direct nor an indirect orthologue in the
human proteome. Therefore, we suggest these pairs as targets for combinatorial
chemotherapy. The comparative genomics pipeline (Fig. 1) is built with self-developed
Python scripts that are available for download at the GitHub repository (https://github
.com/suvi-subra/SynthLeth).
The ﬁnal set of 37 pairs was enriched in druggable proteins (Table 1). Of the 55
proteins in the set, 30 either had been validated as drug targets or had a positive
“druggability index,” as predicted by TDR Targets (17). Some of the suggested combi-
nations affected the same pathway, e.g., the pyridoxal kinase-like protein and pyridox-
ine biosynthesis protein involved in vitamin B6 metabolism or NAD(P)H-dependent
glutamate synthase and NADP-speciﬁc glutamate dehydrogenase; the latter is selec-
tively inhibited by isophthalic acid (18), while glutamate synthase had been suggested
as a target based on comparative genomics (19). Calcineurin subunit B paired with the
P. falciparum cation/H antiporter (PfCHA), which is sensitive to known inhibitors such
as KB-R7943 (20). Hubs of inferred interactions were P. falciparum apurinic/apyrimidinic
endonuclease 1 (PfAPN1) and the P. falciparum U5 small nuclear ribonucleoprotein
(PfSNU114) of the spliceosome, both of which are involved in the processing of nucleic
acids. Two proteins in the target set were of particular pharmacological interest,
namely, P. falciparum Ca2-ATPase 4 (PfATP4) and P. falciparum phosphatidylinositol
4-kinase (PfPI4K). Either protein is targeted by new antimalarial candidates (21–27).
FIG 1 Graphic representation of the algorithm, with the numbers of P. falciparum gene pairs that passed
the ﬁlters; the ﬁnal 37 are shown in Table 1. Yellow, S. cerevisiae; blue, P. falciparum; red, H. sapiens.
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PfATP4 is the target of cipargamin and paired with PfCHA (Table 1), suggesting testing
for potential synergy between cipargamin and KB-R7943. PfPI4K, the target of imida-
zolopiperazines and MMV390048, paired with ubiquitin-conjugating enzyme E2 (Table
1). An inhibitor of Atg8-Atg3 interactions was identiﬁed from the MMV Malaria Box (28),
and ubiquitin-protein ligase E3 was proposed as an antimalarial target (29). The inferred
link between phosphatidylinositol 4-kinase and ubiquitination suggests testing for
potential synergy between PfPI4K inhibitors and P. falciparum proteasome inhibitors
(30–32).
The present approach critically depends on the existence of S. cerevisiae genes that
(i) possess synthetic lethal phenotypes and (ii) are orthologous to known P. falciparum
drug target genes. This seems contradictory; by deﬁnition, drug targets are essential
and genes with synthetic phenotypes are nonessential. However, we show here that
several validated drug targets of P. falciparum possess orthologues in S. cerevisiae that
are nonessential (Table 1). Phosphoethanolamine methyltransferase and phosphatidyl-
inositol 4-kinase (Table 1), for instance, have been demonstrated to be essential
enzymes in P. falciparum (24, 33). Most of the genes that are conserved between S.
cerevisiae and P. falciparum also have an orthologue in H. sapiens (the OrthoMCL
database contains only 80 yeast genes with an orthologue in P. falciparum but not in
TABLE 1 Pairs of P. falciparum proteins suggested as targets for combinatorial chemotherapy, based on synthetic lethal genetic
interactions in S. cerevisiae
Gene 1
identiﬁcation Gene 1 producta
Gene 2
identiﬁcation Gene 2 product
PF14_0492 Calcineurin subunit B PFF0170w Cation/H antiporter
PFL0590c Non-SERCA-type Ca2-transporting P-ATPase 4 PFF0170w Cation/H antiporter
PFE0485w Phosphatidylinositol 4-kinase PFF0305c Ubiquitin-conjugating enzyme E2
PF08_0031 Dicarboxylate/tricarboxylate carrier mal_mito_2 Cytochrome c oxidase subunit 1
PFF1105c Chorismate synthase PF14_0511 Glucose-6-phosphate dehydrogenase
PFL2465c Thymidylate kinase PF13_0176 Apurinic/apyrimidinic endonuclease
MAL13P1.346 DNA repair endonuclease PF13_0176 Apurinic/apyrimidinic endonuclease
PFB0160w ERCC1 nucleotide excision repair protein PF13_0176 Apurinic/apyrimidinic endonuclease
PFF0715c Endonuclease III homologue PF13_0176 Apurinic/apyrimidinic endonuclease
PFD0865c Cdc2-related protein kinase 1 PFF0165c Conserved Plasmodium protein, unknown function
PFL1635w Sentrin-speciﬁc protease 1 PF10_0092 Metallopeptidase
PF13_0251 DNA topoisomerase 3 PF10_0092 Metallopeptidase
PFF0775w Pyridoxal kinase-like protein PFF1025c Pyridoxine biosynthesis protein
PF11_0192 Histone acetyltransferase PFF1180w Anaphase-promoting complex subunit
PFL2440w DNA repair protein MAL7P1.94 Prefoldin subunit 3
PF11_0087 DNA repair protein PF10_0041 U5 small nuclear ribonucleoprotein
PFB0445c ATP-dependent RNA helicase PF10_0041 U5 small nuclear ribonucleoprotein
PFE0925c ATP-dependent RNA helicase PF10_0041 U5 small nuclear ribonucleoprotein
PF10_0294 Pre-mRNA-splicing factor ATP-dependent RNA helicase PF10_0041 U5 small nuclear ribonucleoprotein
PFC1060c U4/U6.U5 tri-small-nuclear-ribonucleoprotein-associated
protein 1
PF10_0041 U5 small nuclear ribonucleoprotein
PF13_0096 U4/U6.U5 tri-small-nuclear-ribonucleoprotein-associated
protein 2
PF10_0041 U5 small nuclear ribonucleoprotein
PFC0365w Pre-mRNA-processing factor 19 PF10_0041 U5 small nuclear ribonucleoprotein
PFD0685c Structural maintenance of chromosomes protein 3 PF10_0041 U5 small nuclear ribonucleoprotein
MAL13P1.214 Phosphoethanolamine N-methyltransferase PFA0455c Fatty acid elongation protein, GNS1/SUR4 family
MAL13P1.214 Phosphoethanolamine N-methyltransferase PFL0950c Aminophospholipid-transporting P-ATPase
MAL8P1.17 Protein disulﬁde isomerase PF10_0092 Metallopeptidase
MAL8P1.17 Protein disulﬁde isomerase PFB0920w DnaJ protein
PF07_0029 Heat shock protein 86 MAL13P1.139 Mitochondrial ﬁssion 1 protein
PF07_0029 Heat shock protein 86 PFI0300w Vacuolar protein sorting-associated protein 46
PF14_0068 rRNA 2=-O-methyltransferase ﬁbrillarin PFF1180w Anaphase-promoting complex subunit
PF14_0261 Proliferation-associated protein 2g4 PF14_0612 Zinc ﬁnger protein
PF14_0286 NADP-speciﬁc glutamate dehydrogenase PF14_0334 NAD(P)H-dependent glutamate synthase
PF14_0401 tRNA import protein PF13_0257 Glutamate-tRNA ligase
PFC0510w E3 ubiquitin-protein ligase PFI0300w Vacuolar protein sorting-associated protein 46
PFE0750c Pre-mRNA-splicing factor PF14_0688 Pre-mRNA-splicing factor ISY1
PFF1385c Conserved Plasmodium protein PFB0920w DnaJ protein
PFL1140w Vacuolar iron transporter PFL0725w Thioredoxin peroxidase 2
aSERCA, sarcoendoplasmic reticulum calcium transport ATPase; ERCC1, excision repair cross-complementation group 1.
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H. sapiens). We speculate that, of the conserved genes that are essential in yeast, many
may also be essential in H. sapiens and their products not suitable as drug targets. On
the other hand, conserved genes that are devoid of synthetic phenotypes in yeast
might also be disposable in P. falciparum and thus not suitable either. The conserved
genes that have synthetic lethal phenotypes in yeast might be the most interesting
pharmacologically.
The proposed algorithm strongly narrows the target space for antimalarial drug
combinations by including potentially synergistic interactions involving efﬁcacy against
P. falciparum as well as toxicity against H. sapiens. The fact that it relies on genome-scale
experimental data from S. cerevisiae rather than P. falciparum makes the algorithm
straightforward and unbiased but also difﬁcult to validate experimentally. Presently,
experimental testing of the identiﬁed target pairs in Table 1 is precluded by the lack of
inhibitors for most of the proposed targets. However, we think that the presence of
targets such as PfPI4K and PfATP4 in Table 1 validates the algorithm, and we hope that
the algorithm will help identify future combinations of antimalarial molecules that
potentiate each other.
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